Cardiac MRI for Detection of Acute and Chronic Cardiac Involvement in Patients With Epilepsy
The Epileptic Heart - Multiparametric Cardiac Magnetic Resonance Imaging for Detection and Quantification of Acute and Chronic Cardiac Involvement in Patients With Epilepsy
The aim of the study is to use multiparametric cardiac MRI to identify any abnormalities in myocardial structure and function in patients with epilepsy. A two-stage study design is planned as part of the study:
- In the acute setting, cardiac MRI will be performed in patients before and after a tonic-clonic seizure and compared intraindividually. In this study arm, potential acute seizure-induced myocardial damage will be detected.
- In the chronic setting, cardiac MRI will be performed in patients with known chronic epilepsy during the seizure-free interval to detect potential chronic myocardial damage (myocardial fibrosis) and compared with a control population. Within the group of epilepsy patients, possible associations with various epilepsy-specific characteristics (e.g., form, cause, onset, duration, and severity of epilepsy) will be investigated.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Julian A. Luetkens, PD Dr.
- Phone Number: +49 228 287 19860
- Email: julian.luetkens@ukbonn.de
Study Contact Backup
- Name: Alexander Isaak, Dr.
- Phone Number: +49 228 287 15960
- Email: alexander.isaak@ukbonn.de
Study Locations
-
-
NRW
-
Bonn, NRW, Germany, 53127
- Recruiting
- University Hospital Bonn, Clinic for Diagnostic and Interventional Radiology
-
Bonn, NRW, Germany, 53127
- Recruiting
- University Hospital Bonn, Clinic and Polyclinic for Epileptology
-
Contact:
- Rainer Surges, Prof.
- Phone Number: +49 228 287 15727
- Email: rainer.surges@ukbonn.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- diagnosed epilepsy
- examination under usual antiepileptic pharmacotherapy or medication up-dosing (if medication was reduced during video-EEG recording)
- age between 18-60 years
Exclusion criteria:
- underlying cardiac disease, e.g. coronary artery disease, previous myocardial infarction, previous myocarditis, complex congenital heart defect, known cardiomyopathy of other cause
- pregnant and breastfeeding women
- patients who use IUD for contraception
- patients with a contraindication to contrast enhanced MRI
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Chronic group
Chronic epilepsy with recurrent seizures
|
Multiparametric cardiac magnetic resonance including traditional and quantitative functional and structural parameters
|
|
Acute group
Epilepsy and short-term history of seizures
|
Multiparametric cardiac magnetic resonance including traditional and quantitative functional and structural parameters
|
|
Control group
Healthy participants
|
Multiparametric cardiac magnetic resonance including traditional and quantitative functional and structural parameters
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
T1 relaxation time
Time Frame: Measurement will be performed within 2 weeks after MRI scan.
|
T1 relaxation times will be obtained to asses acute myocardial injury and fibrosis.
T1 maps will be analyzed using a segmental approach by region of interest analysis.
T1 relaxation times are given in [ms].
|
Measurement will be performed within 2 weeks after MRI scan.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
T2 relaxation time
Time Frame: Measurement will be performed within 2 weeks after MRI scan.
|
T2 relaxation times will be obtained to asses myocardial edema.
T2 maps will be analyzed using a segmental approach by region of interest analysis.
T2 relaxation times are given in [ms].
|
Measurement will be performed within 2 weeks after MRI scan.
|
|
Extracellular volume fraction
Time Frame: Measurement will be performed within 2 weeks after MRI scan.
|
Myocardial extracellular volume will be obtained to asses extracellular space/myocardial fibrosis.
ECV values will be calculated using a segmental approach by region of interest analysis of native and contrast-enhanced T1 relaxation maps.
ECV values are given in [%].
|
Measurement will be performed within 2 weeks after MRI scan.
|
|
Myocardial strain
Time Frame: Measurement will be performed within 2 weeks after MRI scan.
|
Cardiac magnetic resonance feature-tracking will be used to asses left ventricular longitudinal, circumferential and radial strain (Strain values are given in [%]).
|
Measurement will be performed within 2 weeks after MRI scan.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 534/20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NCT03860298CompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant Epilepsy
-
NCT03916848Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, Focal
-
NCT06153186TerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence Epilepsy
-
NCT06310954RecruitingEpilepsy Intractable | Epilepsy in Children
-
NCT00150813CompletedEpilepsy, Tonic-clonic
-
NCT00150787CompletedEpilepsy, Tonic-clonic
-
NCT01311440CompletedEpilepsy | Generalized Epilepsy | Focal Epilepsy
-
NCT03278210CompletedFocal Epilepsy | Epilepsy Intractable
-
NCT06602570Not yet recruitingEpilepsy Intractable | Epilepsy in Children
-
NCT04569708CompletedEpilepsy | Epilepsy; Seizure | Rolandic Epilepsy | Rolandic Epilepsy, Benign | Centrotemporal Epilepsy | Centrotemporal; EEG Spikes, Epilepsy of Childhood
Clinical Trials on Cardiac magnetic resonance scan
-
NCT05041452RecruitingCardiomyopathies | Hypertension, Portal
-
NCT05034588RecruitingCardiomyopathies | Acute Kidney Injury | Cardio-Renal Syndrome
-
NCT05348226CompletedHeart Failure With Reduced Ejection Fraction
-
NCT03058211TerminatedMyocardial Ischemia | Pneumonia, Pneumococcal
-
NCT00965003TerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx Cancer
-
NCT05965258RecruitingIschemic Cardiomyopathy | Functional Mitral Regurgitation | Nonischemic Congestive Cardiomyopathy
-
NCT04584411Not yet recruiting
-
NCT03499197RecruitingMagnetic Resonance Imaging | Heart Transplant Failure and Rejection